Mitchell Steiner
Chief Executive Officer at VERU INC.
Net worth: 9 M $ as of 30/04/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Harry Fisch | M | 65 |
Aspen Park Pharmaceuticals, Inc.
 Aspen Park Pharmaceuticals, Inc. Medical DistributorsDistribution Services Aspen Park Pharmaceuticals, Inc. operated as a therapeutics company that focused on the development of men’s health therapies for medical diseases and conditions. The company was founded by Harry Fisch and Mitchell Shuster Steiner in July 2014 and was headquartered in New York, NY. | 53 years |
| Michele Greco | F | 65 | 11 years | |
| Xiao Qin Lu | M | 49 | 7 years | |
| Dong-Hyun Park | M | 67 | 22 years | |
| Kevin Gilbert | M | - | 7 years | |
| Domingo Rodriguez | M | 62 |
GTx, Inc.
 GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN. | 16 years |
| Philip Greenberg | M | - | - | |
| K. Barnette | M | 56 |
GTx, Inc.
GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN. | 19 years |
| Michael Purvis | M | - | 3 years | |
| Samuel Fisch | M | - | - | |
| Grace Hyun | M | 52 | 4 years | |
| Jeong-Seok Chae | M | 68 | - | |
| Bon-Gwon Gu | M | 57 | - | |
| Mario Eisenberger | M | 74 | 8 years | |
| Jae-Seung Baek | M | 71 | 8 years | |
| Michael Rankowitz | M | 66 | 6 years | |
| T. Bird | M | 71 |
GTx, Inc.
GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN. | 4 years |
| James L. Yeager | M | 78 | 19 years | |
| Martin Clifford Tayler | M | 56 |
The Female Health Company (UK) Plc
 The Female Health Company (UK) Plc Miscellaneous ManufacturingProducer Manufacturing Founded in 1989, The Female Health Company (UK) Plc is a subsidiary of Veru, Inc. that manufactures and sells condoms. The private company is based in London, UK. | - |
| Stephen A. Strugnell | M | - | 10 years | |
| Dae-Shick Oh | M | 69 | 5 years | |
| Peter J. Manso | M | 70 | - | |
| Bill Breitenbach | M | - | 3 years | |
| Denise van Dijk | F | - | - | |
| Sergi Trilla | M | - | 2 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Marc Hanover | M | 61 |
GTx, Inc.
GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN. | - |
| O. B. Parrish | M | 90 | 48 years | |
| Donna Felch | F | 76 | 10 years | |
| Kevin Heinrich | M | - |
University of Tennessee
| 9 years |
| Daniel Haines | M | - |
Aspen Park Pharmaceuticals, Inc.
Aspen Park Pharmaceuticals, Inc. Medical DistributorsDistribution Services Aspen Park Pharmaceuticals, Inc. operated as a therapeutics company that focused on the development of men’s health therapies for medical diseases and conditions. The company was founded by Harry Fisch and Mitchell Shuster Steiner in July 2014 and was headquartered in New York, NY. | 2 years |
| Joseph Hyde | M | 81 |
GTx, Inc.
GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN. | - |
| Mark Mosteller | M | 61 |
GTx, Inc.
GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN. | 12 years |
| John Pontius | M | 68 |
GTx, Inc.
GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN.
University of Tennessee
| 13 years |
| Kevin L. Standefer | M | - |
University of Tennessee
| 10 years |
| Ricky Supan | M | - |
University of Tennessee
| 7 years |
| Jason Shackelford | M | 48 |
GTx, Inc.
GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN. | - |
| Kathryn E. Grooms | F | 39 |
University of Tennessee
| 5 years |
| Brad Morgan | M | - |
University of Tennessee
| 5 years |
| Jody Begley | M | 52 |
University of Tennessee
| 6 years |
| Sharon Meckes | F | 58 | 1 years | |
| Aaron Browning | M | - |
University of Tennessee
| 6 years |
| Andrew L. Douglas | M | - |
University of Tennessee
| 6 years |
| Elgar Peerschke | M | 67 |
Aspen Park Pharmaceuticals, Inc.
Aspen Park Pharmaceuticals, Inc. Medical DistributorsDistribution Services Aspen Park Pharmaceuticals, Inc. operated as a therapeutics company that focused on the development of men’s health therapies for medical diseases and conditions. The company was founded by Harry Fisch and Mitchell Shuster Steiner in July 2014 and was headquartered in New York, NY. | 4 years |
| Georges A. Makhoul | M | 57 | 2 years | |
| Garrett Arms | M | - |
University of Tennessee
| 5 years |
| Jesus Socorro | M | 48 | 4 years | |
| Barrington John Albert Furr | M | 80 |
GTx, Inc.
GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN. | 4 years |
| Nicole Strain | F | 50 |
University of Tennessee
| 6 years |
| Jennifer K. Oswalt | F | - |
University of Tennessee
| 5 years |
| Will Ed Settle | M | - |
University of Tennessee
| 5 years |
| Andrew S. Love | M | 80 | 3 years | |
| Timothy Sear | M | 86 |
GTx, Inc.
GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN. | 9 years |
| Mary Margaret Frank | M | 55 | 14 years | |
| James Dalton | M | 61 |
GTx, Inc.
GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN. | 9 years |
| Rulfo Hernandez | M | 45 | 7 years | |
| Robert Karr | M | 75 |
GTx, Inc.
GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN. | 6 years |
| Jeffrey G. Hesselberg | M | 65 |
GTx, Inc.
GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN. | - |
| Kenneth Robinson | M | 69 |
GTx, Inc.
GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN. | - |
| Holly S. Young | F | - |
University of Tennessee
| 5 years |
| J. Glass | M | 77 |
GTx, Inc.
GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN. | - |
| Henry Doggrell | M | 75 |
GTx, Inc.
GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN. | 18 years |
| David R. Bethune | M | 83 | 23 years | |
| Michael Carter | M | 86 |
GTx, Inc.
GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN. | - |
| Benjamin Brownlow | M | - |
University of Tennessee
| 6 years |
| Kate Inman | F | - | 6 years | |
| Chidinma I. Iwueke | F | - |
University of Tennessee
| 4 years |
| William S. Nuckols | M | - |
University of Tennessee
| 4 years |
| Sarah Gardial | M | 66 |
University of Tennessee
| 8 years |
| Jay Newmark | M | - | 4 years | |
| Kristen Marie Seitz | F | - |
University of Tennessee
| 3 years |
| Amy Gregory | F | - |
University of Tennessee
| 4 years |
| Andrew Ritter | M | - |
University of Tennessee
| 4 years |
| Yi-Xin Wang | M | - |
University of Tennessee
| 4 years |
| Brian Simmons | M | - |
University of Tennessee
| 4 years |
| Todd Stewart | M | - |
University of Tennessee
| 5 years |
| Sanjay Shah | M | 55 |
University of Tennessee
| 4 years |
| Brad McClanahan | M | - |
University of Tennessee
| 4 years |
| Lisa Gunderson | F | - |
University of Tennessee
| 1 years |
| Gregory Deener | M | 62 |
GTx, Inc.
GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN. | 7 years |
| Bill W. Stacy | M | 85 |
University of Tennessee
| 7 years |
| Les Funtleyder | M | 55 | 2 years | |
| Blanding Beatty | M | - |
University of Tennessee
| 3 years |
| Brad Weeks | M | - |
University of Tennessee
| 4 years |
| Tim T. Morris | M | - |
University of Tennessee
| 2 years |
| Keith Townsend | M | - |
University of Tennessee
| 4 years |
| Tom Welch | M | - |
University of Tennessee
| 2 years |
| Prince Y. McKinney | M | - |
University of Tennessee
| 4 years |
| John Swindle | M | - |
University of Tennessee
| 10 years |
| Andrew Bouldin | M | - |
University of Tennessee
| 4 years |
| Narayan Raman | M | 55 |
University of Tennessee
| 3 years |
| Kyle William Johns | M | - |
University of Tennessee
| 4 years |
| Lee Lacy | M | - |
University of Tennessee
| 3 years |
| Nicholas J. Northington | M | - |
University of Tennessee
| 4 years |
| Scott Wyckoff | M | - |
University of Tennessee
| 4 years |
| Robert Bruce Avery | M | 85 |
University of Tennessee
| 29 years |
| Michael W. Berry | M | - |
University of Tennessee
| 12 years |
| Michael Collier | M | 48 |
University of Tennessee
| 6 years |
| Sarah Hope Myers | F | 38 |
University of Tennessee
| 4 years |
| Keith Brakebill | M | 41 |
University of Tennessee
| 4 years |
| Lai Wei | M | 47 |
University of Tennessee
| 3 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 91 | 91.00% |
| South Korea | 8 | 8.00% |
| United Kingdom | 1 | 1.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Mitchell Steiner
- Personal Network